Paper Details

  1. Home
  2. Paper Details

Alcohol use disorder severity moderates clinical response to varenicline.

Author: DonatoSuzanna, GreenReJoyce, RayLara A

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study aims to identify specific characteristics of people with alcohol use disorder (AUD) that predict how well they respond to varenicline, a medication used to reduce alcohol consumption. The study looks at different aspects of AUD severity to better understand which patients are most likely to benefit from varenicline treatment.
Paper Details　
Original Abstract of the Article :
In a multisite clinical trial, varenicline was effective in reducing drinking in both smoking and non-smoking patients with alcohol dependence. Because alcohol use disorder (AUD) is heterogeneous, research aimed at characterizing features associated with treatment response could advance personalized...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/34486130

データ提供：米国国立医学図書館（NLM）

Varenicline for Alcohol Use Disorder: A Tailored Approach

This research explores the effectiveness of varenicline, a medication used to help people quit smoking, in treating alcohol use disorder (AUD). Imagine a camel struggling with a craving for a tasty desert plant, a habit that's becoming difficult to control. Varenicline can be a valuable tool for helping these camels overcome their cravings and find a path to recovery. This study investigates the potential of varenicline for treating AUD, and explores how the severity of the condition may influence treatment response.

Understanding the Nuances of AUD

The researchers found that varenicline was effective in reducing alcohol consumption, but that the severity of AUD impacted the treatment response. This is like recognizing that a camel's ability to overcome a craving for a desert plant depends on how strong the craving is. Those with more severe AUD may require a different approach to treatment.

A Personalized Approach to Recovery

This research highlights the importance of a personalized approach to treating AUD. It underscores the need for careful assessment and individualized treatment plans, taking into account the severity of the disorder. This research suggests that varenicline can be a valuable tool for treating AUD, but it's important to tailor treatment to the individual needs of each patient.

Dr. Camel's Conclusion

This study emphasizes that there is no one-size-fits-all approach to treating AUD. It is crucial to take into account the individual factors affecting each patient's condition and tailor treatment accordingly. This research is a reminder that we need to approach healthcare with empathy, understanding, and a willingness to personalize our interventions for optimal outcomes.

Date :
  1. Date Completed 2022-02-18
  2. Date Revised 2022-09-06
Further Info :

Pubmed ID

34486130

DOI: Digital Object Identifier

NIHMS1735173

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.